DARE

Dare Bioscience, Inc. DARE

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,860 of 2,925

Why it scores 12Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$187.5K

Quarter to Jun 30

Net income

$-2.98M

Quarter to Jun 30

Free cash flow

$-6.86M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$2.75M total
VANGUARD CAPITAL MANAGEMENT LLC
$1.35M+38.6%
GEODE CAPITAL MANAGEMENT, LLC
$295.6K-21.2%
US BANCORP \DE\
$255.1K+32.3%
VANGUARD FIDUCIARY TRUST CO
$192.6K+38.4%
BlackRock, Inc.
$135.6K+278.6%
STATE STREET CORP
$100.0K+101.6%
JANE STREET GROUP, LLC
$76.2KNew
NORTHERN TRUST CORP
$72.2K+121.7%
HRT FINANCIAL LP
$47.0KNew
Virtu Financial LLC
$33.0KNew
LPL Financial LLC
$31.4K+1.7%
RAYMOND JAMES FINANCIAL INC
$31.4K-3.1%
PRICE T ROWE ASSOCIATES INC /MD/
$29.0K+30.3%
StoneX Group Inc.
$24.7KNew
Objectivity Squared, LLC
$23.0K0.0%
Farther Finance Advisors, LLC
$19.9K+1.3%
UBS Group AG
$14.4K-84.3%
Vanguard Global Advisers, LLC
$6.2K0.0%
Bay Harbor Wealth Management, LLC
$2.9KNew
IFS Advisors, LLC
$2.0K0.0%
SBI Securities Co., Ltd.
$1.4K0.0%
JONES FINANCIAL COMPANIES LLLP
$828New
Caitong International Asset Management Co., Ltd
$557New
BARCLAYS PLC
$523New
CALDWELL SUTTER CAPITAL, INC.
$211+488.2%
See all 28 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/DARE

Earnings Per Share

13fpro.ai/company/DARE

Loading ratio trend…

DARE key financials by period

Reported revenue, net income and operating margin by fiscal year, from Dare Bioscience, Inc.'s annual filings on SEC EDGAR.

Dare Bioscience, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$1.0M$-13.4M—
FY 2024$9.8K$-4.1M—
FY 2023$2.8M$-30.2M—
FY 2022$10.0M$-30.9M—
FY 2016$766.0K$-39.3M-82.3%
FY 2014$80.0K$-23.3M—
Source: DARE filings on SEC EDGAR →

DARE insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Dare Bioscience, Inc. (DARE): stock profile, AI score and financials

Dare Bioscience, Inc. (DARE) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DARE at 11.5/100 on a composite quality score built from its SEC filings, placing it at rank #2,860 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Dare Bioscience, Inc. reports quarterly revenue of $187.5K, net income of $-3.0M, free cash flow of $-6.9M. Top institutional holders of DARE by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT, US BANCORP \DE\, based on the most recent SEC filings. DARE trades on the Nasdaq exchange and files with the SEC under CIK 1401914. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DARE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Dare Bioscience, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1401914 →